Ayse Sagduyu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ayse Sagduyu has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Nur Yüceyar
Department of Neurology, Ege University Faculty of Medicine, Izmir, Turkey
5 shared publications - Emre Kumral
Department of Neurology, Faculty of Medicine, Ege University, Izmir, Turkey
3 shared publications - Aksel Siva
Cerrahpasa School of Medicine, Istanbul University, Turkey
2 shared publications C. Calli
Department of Neuroradiology, Ege University School of Medicine, İzmir, Turkey
2 shared publications- Cihat Uzunkopru
Department of Neurology, Katip Celebi University School of Medicine, Izmir, Turkey
2 shared publications - Dilek Taskiran
EGE TIP FAKÜLTESİ
2 shared publications
Latest Publications
- 19 February 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (6) , 2737-2746
Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population
Objectives This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists. Methods Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics. Results The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years. Conclusion Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.
- 19 February 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (6) , 2737-2746
Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population
Objectives This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists. Methods Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics. Results The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years. Conclusion Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.
- 1 January 2020
- Published by Turkish Society of Cerebrovascular Diseases in Turkish Journal of Cerebrovascular Diseases
- Vol. 26 (1) , 95-106
Acute ischemic stroke; etiopathogenetic classification, neuroradiological, clinical, prognostic correlation
- 1 January 2020
- Published by Turkish Society of Cerebrovascular Diseases in Turkish Journal of Cerebrovascular Diseases
- Vol. 26 (1) , 95-106
Acute ischemic stroke; etiopathogenetic classification, neuroradiological, clinical, prognostic correlation
- Open Access
- 14 April 2014
- Published by Hindawi Limited in Behavioural Neurology
- Vol. 2014, 1-5
Assessment of Early Cognitive Impairment in Patients with Clinically Isolated Syndromes and Multiple Sclerosis
Objective. The aim of our study was to investigate the frequency and pattern of cognitive impairment in patients with clinically isolated syndromes and definite diagnosis of multiple sclerosis within the last 2 years.Methods. We assessed the cognitive status of 46 patients aged 18–49 years with clinically isolated syndromes or definite diagnosis of multiple sclerosis who have onset of their symptoms within the last 2 years. Patients were matched with 40 healthy participants for age, sex, and educational level. Neuropsychological assessment was performed by stroop test, paced auditory serial addition test (PASAT), controlled oral word association test (COWAT), clock drawing test, trail making test (TMT), faces symbol test (FST). Hamilton Depression Scale and Modified Fatigue Impact Scale were used to quantify the severity of any depression and fatigue the subjects might suffer.Results. 19.6% of early MS/CIS group failed at 4 and more tests and had significant cognitive impairment focused on attention, executive functions, memory, and learning. No significant relationship was found between cognitive impairment and disability and fatigue scores.Discussion. Cognitive impairment can be present from the earliest stage of multiple sclerosis. It should be considered among the main manifestations of MS even in the earliest stages of the disease.
- 14 April 2014
- Published by Hindawi Limited in Behavioural Neurology
- Vol. 2014, 1-5
Open AccessAssessment of Early Cognitive Impairment in Patients with Clinically Isolated Syndromes and Multiple Sclerosis
Objective. The aim of our study was to investigate the frequency and pattern of cognitive impairment in patients with clinically isolated syndromes and definite diagnosis of multiple sclerosis within the last 2 years.Methods. We assessed the cognitive status of 46 patients aged 18–49 years with clinically isolated syndromes or definite diagnosis of multiple sclerosis who have onset of their symptoms within the last 2 years. Patients were matched with 40 healthy participants for age, sex, and educational level. Neuropsychological assessment was performed by stroop test, paced auditory serial addition test (PASAT), controlled oral word association test (COWAT), clock drawing test, trail making test (TMT), faces symbol test (FST). Hamilton Depression Scale and Modified Fatigue Impact Scale were used to quantify the severity of any depression and fatigue the subjects might suffer.Results. 19.6% of early MS/CIS group failed at 4 and more tests and had significant cognitive impairment focused on attention, executive functions, memory, and learning. No significant relationship was found between cognitive impairment and disability and fatigue scores.Discussion. Cognitive impairment can be present from the earliest stage of multiple sclerosis. It should be considered among the main manifestations of MS even in the earliest stages of the disease.
- 5 August 2013
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 50 (1) , 36-40
Migren Tedavisinde Botulinum Toksini
Since botulinum toxin might have a therapeutic effect on pain, many studies investigating the efficiency of botulinum toxin in headache treatment have been done. The most satisfying results were achieved by botulinum toxin type A (BoNT/A) in the treatment of chronic migraine. In this paper, we reviewed the clinical effectiveness of BoNT/A in migraine and included our clinical experience. In our ongoing pilot study, where we have repeated BoNT/A injections every 12 weeks, The difference in the Migraine Disability Assessment (MIDAS) scores between the first and the second injections was 61.1%; and between the first and the 3rd injections was found to be 65.72%. (Archives of Neuropsychiatry 2013; 50 Supplement 1: 36-40)Conflict of interest: The authors reported no conflict of interest related to this article
- 5 August 2013
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 50 (1) , 36-40
Migren Tedavisinde Botulinum Toksini
Since botulinum toxin might have a therapeutic effect on pain, many studies investigating the efficiency of botulinum toxin in headache treatment have been done. The most satisfying results were achieved by botulinum toxin type A (BoNT/A) in the treatment of chronic migraine. In this paper, we reviewed the clinical effectiveness of BoNT/A in migraine and included our clinical experience. In our ongoing pilot study, where we have repeated BoNT/A injections every 12 weeks, The difference in the Migraine Disability Assessment (MIDAS) scores between the first and the second injections was 61.1%; and between the first and the 3rd injections was found to be 65.72%. (Archives of Neuropsychiatry 2013; 50 Supplement 1: 36-40)Conflict of interest: The authors reported no conflict of interest related to this article
- Open Access
- 1 September 2012
- Published by Turk Noroloji Dernegi in Turkish Journal Of Neurology
- Vol. 18 (3) , 118-122
Karbonmonoksit İntoksikasyonuna Bağlı Gecikmiş Ensefalopati ve Hiperbarik Oksijen Uygulaması: Olgu Sunumu
- 1 September 2012
- Published by Turk Noroloji Dernegi in Turkish Journal Of Neurology
- Vol. 18 (3) , 118-122
Open AccessKarbonmonoksit İntoksikasyonuna Bağlı Gecikmiş Ensefalopati ve Hiperbarik Oksijen Uygulaması: Olgu Sunumu
- 14 March 2012
- Published by S. Karger AG in European Neurology
- Vol. 67 (4) , 239
Letter to the Editor
- 18 June 2011
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 35 (3) , 115-120
Optic Neuritis: Visual Outcome and Risk Factors for the Development of Multiple Sclerosis in Western Turkey
Optic neuritis (ON) is highly associated with multiple sclerosis (MS) and conversion rate has been reported to be around 50% over a period of 15 years. We revised the risk factors for developing MS after an attack of ON, in western Turkey. One hundred and twenty-four patients with acute unilateral ON, who were on follow-up for at least 5 years (range 62 to180 months, mean 85 months) were enrolled in the study. Gender, age at onset, seasonal occurrence, severity of visual loss, presence of pain, optic disc appearance, treatment, degree of recovery, presence or absence of lesions on magnetic resonance imaging (MRI) during the initial ON attack and recurrence were considered. Of the 124 patients, 89 (71.8%) were women, 35 (28.2%) were men, with a mean age of 28.7 ± 8.6 years at the time of the initial ON attack. During follow-up, 70 patients (56.5%) developed MS within 17.14 months, ranging from 1 to 125 months. Female gender (p = 0.021), experiencing the attack before 40 years of age (p = 0.02), normal-appearing optic discs (p = 0.005), presence of MRI lesions (p < 0.001), and recurring ON attacks (p = 0.014) were significantly associated with a high risk of developing MS. The period for development of MS was significantly shorter in patients with MRI lesions (p < 0.001). Optic neuritis patients with brain MRI findings showing the morphological evidence of disseminated disease can be considered to have MS at the time of the initial ON attack, and disease-modifying treatments can be initiated.
- 18 June 2011
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 35 (3) , 115-120
Optic Neuritis: Visual Outcome and Risk Factors for the Development of Multiple Sclerosis in Western Turkey
Optic neuritis (ON) is highly associated with multiple sclerosis (MS) and conversion rate has been reported to be around 50% over a period of 15 years. We revised the risk factors for developing MS after an attack of ON, in western Turkey. One hundred and twenty-four patients with acute unilateral ON, who were on follow-up for at least 5 years (range 62 to180 months, mean 85 months) were enrolled in the study. Gender, age at onset, seasonal occurrence, severity of visual loss, presence of pain, optic disc appearance, treatment, degree of recovery, presence or absence of lesions on magnetic resonance imaging (MRI) during the initial ON attack and recurrence were considered. Of the 124 patients, 89 (71.8%) were women, 35 (28.2%) were men, with a mean age of 28.7 ± 8.6 years at the time of the initial ON attack. During follow-up, 70 patients (56.5%) developed MS within 17.14 months, ranging from 1 to 125 months. Female gender (p = 0.021), experiencing the attack before 40 years of age (p = 0.02), normal-appearing optic discs (p = 0.005), presence of MRI lesions (p < 0.001), and recurring ON attacks (p = 0.014) were significantly associated with a high risk of developing MS. The period for development of MS was significantly shorter in patients with MRI lesions (p < 0.001). Optic neuritis patients with brain MRI findings showing the morphological evidence of disseminated disease can be considered to have MS at the time of the initial ON attack, and disease-modifying treatments can be initiated.
- 1 October 2008
- Published by Elsevier in Neuromuscular Disorders
- Vol. 18 (9-10) , 788
G.P.9.08 Severe cardiomyopathy in hyaline body myopathy: Ten years of follow-up
- 1 October 2008
- Published by Elsevier in Neuromuscular Disorders
- Vol. 18 (9-10) , 788
G.P.9.08 Severe cardiomyopathy in hyaline body myopathy: Ten years of follow-up
- 1 October 2006
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 114 (4) , 254-260
Cerebral cortical and deep venous thrombosis without sinus thrombosis: clinical MRI correlates
Cortical and/or deep vein thrombosis (CDVT) without dural sinus involvement is uncommon and presents diagnostic difficulty for many reasons. Our aim is to determine the relationship between magnetic resonance imaging (MRI) findings and clinical findings in patients with CDVT. Forty-six patients with venous stroke proved on MRI included in our Registry, corresponding to 0.1% of 4650 patients with stroke, were studied. Magnetic resonance angiography (MRA) was performed in all patients, and 18 of them had follow-up MRA. Outcome was evaluated by using the Glasgow Outcome Scale at the time of discharge and during follow-up. Thirty-two patients presented cortical venous stroke; 21 of them had involvement of the dorsomedial venous system, six had a defect in the posteroinferior venous group, and five had a defect in the anteroinferior venous group. Thirteen patients presented simultaneous involvement of the superficial and deep venous system; seven with a defect in the parietal and internal cerebral veins (three with involvement of vein of Gallen), four with a defect in the temporooccipital (vein of Labbé) and basal vein of Rosenthal, two with a deficit in the anterior frontotemporal and uncal-pterygoid venous system. One patient had deep venous thrombosis primarily localized to the thalami bilaterally and the basal ganglia on the right because of occlusion of the thalamostriate veins. The main presenting symptoms of CDVT were headache, focal neurologic signs, partial complex or secondary generalized seizures, and consciousness disturbances in those with deep venous thrombosis, presented alone or in combination at onset. CDVT was more than twofold more frequent in women than in men. Pregnancy, puerperium, oral contraceptive use, and infections were the most common predisposing factors. Computerized tomography, conventional MRI and diffusion-weighted imaging showing ischemic and/or hemorrhagic lesion that does not follow the boundary of classical arterial boundaries without signs of sinus thrombosis, and partial or generalized seizures followed by focal neurologic signs may predict CDVT. The outcome of patients with cortical venous stroke was good, but not in those with cortical plus deep venous infarction.
- 1 October 2006
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 114 (4) , 254-260
Cerebral cortical and deep venous thrombosis without sinus thrombosis: clinical MRI correlates
Cortical and/or deep vein thrombosis (CDVT) without dural sinus involvement is uncommon and presents diagnostic difficulty for many reasons. Our aim is to determine the relationship between magnetic resonance imaging (MRI) findings and clinical findings in patients with CDVT. Forty-six patients with venous stroke proved on MRI included in our Registry, corresponding to 0.1% of 4650 patients with stroke, were studied. Magnetic resonance angiography (MRA) was performed in all patients, and 18 of them had follow-up MRA. Outcome was evaluated by using the Glasgow Outcome Scale at the time of discharge and during follow-up. Thirty-two patients presented cortical venous stroke; 21 of them had involvement of the dorsomedial venous system, six had a defect in the posteroinferior venous group, and five had a defect in the anteroinferior venous group. Thirteen patients presented simultaneous involvement of the superficial and deep venous system; seven with a defect in the parietal and internal cerebral veins (three with involvement of vein of Gallen), four with a defect in the temporooccipital (vein of Labbé) and basal vein of Rosenthal, two with a deficit in the anterior frontotemporal and uncal-pterygoid venous system. One patient had deep venous thrombosis primarily localized to the thalami bilaterally and the basal ganglia on the right because of occlusion of the thalamostriate veins. The main presenting symptoms of CDVT were headache, focal neurologic signs, partial complex or secondary generalized seizures, and consciousness disturbances in those with deep venous thrombosis, presented alone or in combination at onset. CDVT was more than twofold more frequent in women than in men. Pregnancy, puerperium, oral contraceptive use, and infections were the most common predisposing factors. Computerized tomography, conventional MRI and diffusion-weighted imaging showing ischemic and/or hemorrhagic lesion that does not follow the boundary of classical arterial boundaries without signs of sinus thrombosis, and partial or generalized seizures followed by focal neurologic signs may predict CDVT. The outcome of patients with cortical venous stroke was good, but not in those with cortical plus deep venous infarction.